Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Facet, genicular, and basivertebral nerve ablation. Main billing specialties: pain management and physical medicine.
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 451 | 40,806+0.5%/yr | +0.5%/yr | 17.41.6× | 95% | 48,900 in 2030+3.1%/yr |
| Texas | 464 | 34,513−0.2%/yr | −0.2%/yr | 15.21.4× | 78% | 40,900 in 2030+2.9%/yr |
| California | 375 | 24,956+2.5%/yr | +2.5%/yr | 7.10.7× | 86% | 32,700 in 2030+4.6%/yr |
| Arizona | 185 | 17,395+0.3%/yr | +0.3%/yr | 22.42.1× | 93% | 19,600 in 2030+2%/yr |
| New York | 223 | 14,264−0.1%/yr | −0.1%/yr | 7.50.7× | 81% | 18,300 in 2030+4.2%/yr |
| Georgia | 191 | 13,392−3%/yr | −3%/yr | 14.71.4× | 91% | 15,000 in 2030+1.9%/yr |
| Pennsylvania | 205 | 12,153+2.9%/yr | +2.9%/yr | 8.50.8× | 63% | 14,300 in 2030+2.7%/yr |
| Illinois | 165 | 12,036+1%/yr | +1%/yr | 8.40.8× | 66% | 13,800 in 2030+2.3%/yr |
| North Carolina | 172 | 11,392−0.4%/yr | −0.4%/yr | 10.91.0× | 82% | 12,200 in 2030+1.2%/yr |
| Virginia | 121 | 10,959+2.8%/yr | +2.8%/yr | 10.10.9× | 80% | 13,100 in 2030+3%/yr |
| Ohio | 179 | 10,830−5.3%/yr | −5.3%/yr | 9.30.9× | 43% | 11,600 in 2030+1.2%/yr |
| Oklahoma | 78 | 8,975+3.6%/yr | +3.6%/yr | 17.81.7× | 65% | 11,900 in 2030+4.8%/yr |
| Louisiana | 95 | 8,745+0.5%/yr | +0.5%/yr | 20.31.9× | 63% | 10,700 in 2030+3.4%/yr |
| Maryland | 110 | 8,602−0.5%/yr | −0.5%/yr | 9.50.9× | 97% | 8,640 in 2030+0.1%/yr |
| Tennessee | 111 | 8,564+0.4%/yr | +0.4%/yr | 11.61.1× | 88% | 10,900 in 2030+4.2%/yr |
| South Carolina | 107 | 7,768−1.3%/yr | −1.3%/yr | 10.91.0× | 87% | 8,970 in 2030+2.4%/yr |
| Michigan | 128 | 7,269−3.7%/yr | −3.7%/yr | 8.10.8× | 75% | 8,240 in 2030+2.1%/yr |
| Arkansas | 73 | 7,188−5.6%/yr | −5.6%/yr | 18.31.7× | 76% | 7,600 in 2030+0.9%/yr |
| Massachusetts | 107 | 7,050+1.9%/yr | +1.9%/yr | 7.20.7× | 43% | 9,910 in 2030+5.8%/yr |
| Kentucky | 75 | 6,856−6.1%/yr | −6.1%/yr | 14.21.3× | 81% | 7,510 in 2030+1.5%/yr |
| New Jersey | 112 | 6,842−0.4%/yr | −0.4%/yr | 6.30.6× | 86% | 9,070 in 2030+4.8%/yr |
| Indiana | 117 | 6,614−1.7%/yr | −1.7%/yr | 9.00.8× | 71% | 8,050 in 2030+3.3%/yr |
| Utah | 70 | 6,327+1.2%/yr | +1.2%/yr | 27.52.6× | 82% | 7,570 in 2030+3%/yr |
| Colorado | 95 | 6,258+2.1%/yr | +2.1%/yr | 12.21.1× | 84% | 8,230 in 2030+4.7%/yr |
| Missouri | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.50.9× | 28% | 8,640 in 2030+5.8%/yr |
| Wisconsin | 107 | 5,630−0.5%/yr | −0.5%/yr | 9.50.9× | 45% | 6,580 in 2030+2.6%/yr |
| Mississippi | 50 | 4,876+2%/yr | +2%/yr | 12.51.2× | 86% | 7,510 in 2030+7.5%/yr |
| Alabama | 71 | 4,863+1.6%/yr | +1.6%/yr | 10.51.0× | 74% | 6,430 in 2030+4.8%/yr |
| Minnesota | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.10.9× | 73% | 6,880 in 2030+6.1%/yr |
| Washington | 75 | 4,700−0.3%/yr | −0.3%/yr | 5.90.5× | 77% | 5,550 in 2030+2.8%/yr |
| Nevada | 54 | 3,899−4.7%/yr | −4.7%/yr | 12.91.2× | 98% | 4,350 in 2030+1.8%/yr |
| Oregon | 49 | 3,673+3.6%/yr | +3.6%/yr | 8.30.8× | 97% | 5,130 in 2030+5.7%/yr |
| Kansas | 57 | 3,413+4%/yr | +4%/yr | 8.20.8× | 46% | 4,450 in 2030+4.5%/yr |
| Nebraska | 37 | 2,646+7.2%/yr | +7.2%/yr | 9.80.9× | 71% | 4,000 in 2030+7.1%/yr |
| New Mexico | 39 | 2,542+2.5%/yr | +2.5%/yr | 10.51.0× | 73% | 3,290 in 2030+4.4%/yr |
| Iowa | 36 | 2,386+2.2%/yr | +2.2%/yr | 5.20.5× | 62% | 2,800 in 2030+2.7%/yr |
| Connecticut | 35 | 2,271−2.6%/yr | −2.6%/yr | 6.50.6× | 94% | 3,630 in 2030+8.1%/yr |
| Idaho | 27 | 2,085+4.8%/yr | +4.8%/yr | 9.80.9× | 42% | 3,470 in 2030+8.9%/yr |
| New Hampshire | 34 | 2,030+2.3%/yr | +2.3%/yr | 8.70.8× | 67% | 3,060 in 2030+7.1%/yr |
| West Virginia | 24 | 1,871−2.4%/yr | −2.4%/yr | 8.50.8× | 17% | 2,300 in 2030+3.5%/yr |
| Delaware | 24 | 1,803+8.7%/yr | +8.7%/yr | 10.20.9× | 100% | 3,040 in 2030+9.1%/yr |
| South Dakota | 16 | 1,153−1.6%/yr | −1.6%/yr | 8.60.8× | 12% | 1,270 in 2030+1.6%/yr |
| Montana | 25 | 973−0.6%/yr | −0.6%/yr | 5.00.5× | 49% | 1,190 in 2030+3.4%/yr |
| Maine | 16 | 850−3.9%/yr | −3.9%/yr | 5.10.5× | 26% | 730 in 2030−2.5%/yr |
| North Dakota | 12 | 670−3.9%/yr | −3.9%/yr | 6.50.6× | 37% | 740 in 2030+1.8%/yr |
| Alaska | 10 | 623−2.3%/yr | −2.3%/yr | 5.20.5× | 92% | 780 in 2030+3.7%/yr |
| Rhode Island | 12 | 502+15%/yr | +15%/yr | 5.20.5× | 75% | 740 in 2030+6.6%/yr |
| Wyoming | 5 | 424+10%/yr | +10%/yr | 3.80.4× | 51% | 1,010 in 2030+16%/yr |
| Vermont | 9 | 412−4.3%/yr | −4.3%/yr | 3.50.3× | 12% | 670 in 2030+8.3%/yr |
| District of Columbia | 9 | 229−7.4%/yr | −7.4%/yr | 3.50.3× | 96% | 240 in 2030+0.9%/yr |
| Hawaii | 2 | 164−13%/yr | −13%/yr | 1.20.1× | 95% | 250 in 2030+7.2%/yr |
Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 29 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 15 companies. The most active:
Product codes: GXD (generator, lesion, radiofrequency), GXI (probe, radiofrequency lesion). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 12% of the cases CMS names in Florida; 208 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 597 | 37,794+7.9%/yr | +7.9%/yr | 64,500 in 2030+9.3%/yr |
| Spinal cord & DRG stimulation | 668 | 24,248−3.1%/yr | −3.1%/yr | 28,100 in 2030+2.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 12 companies reported engagement with surgeons in the covered states worth $5.5M in consulting, speaking, meals and travel tied to these products, about $1,094 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.